Literature DB >> 10998083

Apolipoprotein E-deficient mice have an impaired immune response to Klebsiella pneumoniae.

N de Bont1, M G Netea, P N Demacker, B J Kullberg, J W van der Meer, A F Stalenhoef.   

Abstract

BACKGROUND: All lipoproteins are able to bind to bacterial lipopolysaccharide (LPS), thereby neutralizing its deleterious effects. However, we demonstrated, recently, that in the absence of apolipoprotein E (apoE), eight-fold increased very-low-density lipoprotein levels were not sufficient to protect apoE-deficient (apoE-/-) mice against LPS. During a live Gram-negative infection, mechanisms other than LPS-neutralization may play a role in the pathogenesis of the disease. In the present study we further examined the role of apoE in Gram-negative sepsis.
METHODS: Survival, bacterial outgrowth in liver, spleen, kidneys and blood, and tumour necrosis factor-alpha (TNF-alpha) production were measured in apoE-/- mice and control C57BL/6J mice, after an intravenous infection with Klebsiella pneumoniae.
RESULTS: Mice that lack apoE showed higher mortality in response to K. pneumoniae than control mice (90% vs. 23% respectively after 2 weeks). ApoE-/- mice had 10-100 times more outgrowth of the bacteria in their organs than controls. Furthermore, circulating TNF-alpha concentrations 90 min after a challenge, were almost twice as high in the apoE-/- mice compared to controls (13.0 +/- 2.9 ng mL-1 vs. 7.6 +/- 3.8 ng mL-1). When apoE-/- and control mice were rendered neutropenic, the discrepancy in survival and outgrowth of K. pneumoniae disappeared.
CONCLUSIONS: The apoE-/- mice were more susceptible than control C57BL/6 mice to a K. pneumoniae infection. The absence of apoE may render these mice more susceptible, since this protein is of importance in the detoxification of lipopolysaccharide of Gram-negative bacteria. On the other hand, the phagocytic capacity of granulocytes seems to be decreased in apoE-/- mice, resulting in increased outgrowth and mortality.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10998083     DOI: 10.1046/j.1365-2362.2000.00715.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  29 in total

Review 1.  Anti-inflammatory and cholesterol-reducing properties of apolipoprotein mimetics: a review.

Authors:  C Roger White; David W Garber; G M Anantharamaiah
Journal:  J Lipid Res       Date:  2014-08-25       Impact factor: 5.922

2.  APOε4 is associated with enhanced in vivo innate immune responses in human subjects.

Authors:  Stephen C Gale; Li Gao; Carmen Mikacenic; Susette M Coyle; Nicholas Rafaels; Tanda Murray Dudenkov; Jennifer H Madenspacher; David W Draper; William Ge; Jim J Aloor; Kathleen M Azzam; Lihua Lai; Perry J Blackshear; Steven E Calvano; Kathleen C Barnes; Stephen F Lowry; Siobhan Corbett; Mark M Wurfel; Michael B Fessler
Journal:  J Allergy Clin Immunol       Date:  2014-03-18       Impact factor: 10.793

3.  The Apolipoprotein E Mimetic Peptide AEM-2 Attenuates Mitochondrial Injury And Apoptosis In Human THP-1 Macrophages.

Authors:  Samantha Giordano-Mooga; Geeta Datta; Paul Wolkowicz; David W Garber; Mayakonda Palgunachari; C Roger White; G M Anantharamaiah
Journal:  Curr Top Pept Protein Res       Date:  2018

4.  Novel method for reducing plasma cholesterol: a ligand replacement therapy.

Authors:  G M Anantharamaiah; Dennis Goldberg
Journal:  Clin Lipidol       Date:  2015-01-01

Review 5.  The role of apolipoprotein E in Guillain-Barré syndrome and experimental autoimmune neuritis.

Authors:  Hong-liang Zhang; Jiang Wu; Jie Zhu
Journal:  J Biomed Biotechnol       Date:  2010-02-16

Review 6.  Impact of environmental factors on alloimmunity and transplant fate.

Authors:  Leonardo V Riella; Jessamyn Bagley; John Iacomini; Maria-Luisa Alegre
Journal:  J Clin Invest       Date:  2017-05-08       Impact factor: 14.808

7.  Apolipoprotein E epsilon 4 is associated with an increased vulnerability to cell death in Alzheimer's disease.

Authors:  C Frey; A Bonert; T Kratzsch; G Rexroth; W Rösch; F Müller-Spahn; K Maurer; W E Müller; A Eckert
Journal:  J Neural Transm (Vienna)       Date:  2006-06-01       Impact factor: 3.575

8.  Roles of the Mevalonate Pathway and Cholesterol Trafficking in Pulmonary Host Defense.

Authors:  Kristin A Gabor; Michael B Fessler
Journal:  Curr Mol Pharmacol       Date:  2017       Impact factor: 3.339

Review 9.  Impact of hyperlipidemia on alloimmunity.

Authors:  Jessamyn Bagley; Jin Yuan; John Iacomini
Journal:  Curr Opin Organ Transplant       Date:  2017-02       Impact factor: 2.640

10.  Hyperlipidemia offers protection against Leishmania donovani infection: role of membrane cholesterol.

Authors:  June Ghosh; Shantanabha Das; Rajan Guha; Debopam Ghosh; Kshudiram Naskar; Anjan Das; Syamal Roy
Journal:  J Lipid Res       Date:  2012-10-10       Impact factor: 5.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.